2. Search Result
Search Result
Results for "

light chain

" in MedChemExpress (MCE) Product Catalog:

199

Inhibitors & Agonists

2

Biochemical Assay Reagents

9

Peptides

1

MCE Kits

215

Inhibitory Antibodies

2

Natural
Products

16

Recombinant Proteins

16

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99481
    Birtamimab

    NEOD001

    		 Amyloid-β Neurological Disease
    Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
    Birtamimab
  • HY-126913
    Rhodblock 6

    		ROCK Cancer
    Rhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization .
    Rhodblock 6
  • HY-P990785
    Etentamig

    ABBV-383; TNB 383B

    		 CD3 Cardiovascular Disease Inflammation/Immunology Cancer
    Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
    Etentamig
  • HY-116420
    ROCK2-IN-8

    		ROCK Neurological Disease
    ROCK2-IN-8 (Compound 1) is an orally active ROCK2 inhibitor, with an IC50 of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .
    ROCK2-IN-8
  • HY-100912
    W-7 hydrochloride
    5 Publications Verification

    		 Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Cancer
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively . W-7 hydrochloride induces apoptosis and has antitumor activity .
    W-7 hydrochloride
  • HY-P5998
    Myosin Light Chain Kinase Substrate (smooth muscle)

    		Myosin Cancer
    Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate .
    Myosin Light Chain Kinase Substrate (smooth muscle)
  • HY-P10346
    smMLCK peptide

    Smooth-Muscle Myosin light-chain Kinase (796-815)

    		 Myosin Cardiovascular Disease Inflammation/Immunology
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .
    smMLCK peptide
  • HY-145890
    LC kinetic stabilizer-2

    		Amyloid-β Inflammation/Immunology
    LC kinetic stabilizer-2 is a potent  amyloidogenic immunoglobulin light chain (LC) kinetic stabilizer with an EC50 of 24 nM .
    LC kinetic stabilizer-2
  • HY-145889
    LC kinetic stabilizer-1

    		Biochemical Assay Reagents Others
    LC kinetic stabilizer-1 (compound 21) is a potent and selective amyloidogenic immunoglobulin light chain kinetic stabilizer with EC50s of 140 and 74.1 nM for WIL-FL * and WIL-FL * T46L/F49Y, respectively. WIL-FL is an amyloidogenic FL LC dimer .
    LC kinetic stabilizer-1
  • HY-P10628
    β Amyloid (1-14), human

    		Amyloid-β Neurological Disease
    β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
    β Amyloid (1-14), human
  • HY-P99325
    Toralizumab

    IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

    		 TNF Receptor Inflammation/Immunology
    Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
    Toralizumab
  • HY-P2162
    Kemptamide

    		Myosin Cancer
    Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
    Kemptamide
  • HY-P990757
    Ragistomig

    		TNF Receptor PD-1/PD-L1 Inflammation/Immunology
    Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains .
    Ragistomig
  • HY-P990718
    Cemavafusp

    		PD-1/PD-L1 Inflammation/Immunology
    Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
    Cemavafusp
  • HY-P990695
    Lunaxafusp

    		EGFR Inflammation/Immunology
    Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
    Lunaxafusp
  • HY-169426
    Anti-amyloid agent-2

    		Amyloid-β Cancer
    Anti-amyloid agent-2 (compound (R)-38) is an amyloidogenic immunoglobulin light chain stabilizer .
    Anti-amyloid agent-2
  • HY-18671
    BoNT-IN-1

    		Bacterial Antibiotic Neurological Disease
    BoNT-IN-1 is an effective inhibitor of botulinum toxin type A light chain (BoNTA LC), with an IC50 value of 0.9 μM.
    BoNT-IN-1
  • HY-100685
    MS-444
    1 Publications Verification

    BE-34776

    		 Myosin Cancer
    MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
    MS-444
  • HY-111535
    BoNT-IN-2

    		Bacterial Others
    BoNT-IN-2 (Compound 33) is a Botulinum Neurotoxin A Light Chain (BoNT/A LC) inhibitor with an IC50 of 4.5 μM .
    BoNT-IN-2
  • HY-169183
    Myokinasib-II

    		Myosin Cancer
    Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases. .
    Myokinasib-II
  • HY-P10165
    MLCK Peptide

    		Calmodulin Metabolic Disease
    MLCK Peptide is a fully reversible, high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase .
    MLCK Peptide
  • HY-129616
    TachypleginA-2

    		Parasite Infection
    TachypleginA-2 is a small-molecule inhibitor of parasite motility and invasion. TachypleginA-2 reproducibly induces the TgMLC1 (an essential light chain) mobility shift .
    TachypleginA-2
  • HY-P1029
    MLCK inhibitor peptide 18
    4 Publications Verification

    		 Myosin CaMK Autophagy Others
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
  • HY-P990373
    Anti-CLEC4C Antibody

    		C-type Lectin-like Receptors (CTLRs) Inflammation/Immunology
    Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
    Anti-CLEC4C Antibody
  • HY-P990571
    Coltuximab

    		CD19 Inflammation/Immunology
    Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Coltuximab
  • HY-P990673
    Vandortuzumab

    		Transmembrane Glycoprotein Inflammation/Immunology
    Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Vandortuzumab
  • HY-P990631
    Mibavademab

    		Neuropeptide Y Receptor Inflammation/Immunology
    Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Mibavademab
  • HY-P990587
    FR104

    		CD28 Inflammation/Immunology
    FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    FR104
  • HY-P990464
    Anti-Matriptase Antibody

    		Ser/Thr Protease Inflammation/Immunology
    Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Matriptase Antibody
  • HY-P990480
    Anti-oxLDL Antibody

    		LDLR Inflammation/Immunology
    The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-oxLDL Antibody
  • HY-P990669
    Torudokimab

    		Interleukin Related Inflammation/Immunology
    Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Torudokimab
  • HY-P990662
    Sapelizumab

    		Interleukin Related Inflammation/Immunology
    Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    Sapelizumab
  • HY-P990466
    Anti-Mesothelin Antibody

    		Mesothelin Inflammation/Immunology
    Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Mesothelin Antibody
  • HY-P990431
    Anti-HGFA Antibody

    		Ser/Thr Protease Inflammation/Immunology
    Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-HGFA Antibody
  • HY-P990564
    Senlizumab

    BAY-103356; CDP-571

    		 TNF Receptor Inflammation/Immunology
    Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Senlizumab
  • HY-P990642
    Oportuzumab

    		Transmembrane Glycoprotein Inflammation/Immunology
    Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Oportuzumab
  • HY-P990675
    VGX-100

    		VEGFR Inflammation/Immunology
    VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    VGX-100
  • HY-P990622
    MB-311

    		Transmembrane Glycoprotein Inflammation/Immunology
    MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    MB-311
  • HY-P990532
    Anti-TPBG Antibody

    		Wnt Inflammation/Immunology
    Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TPBG Antibody
  • HY-P990318
    Alacizumab

    		VEGFR Inflammation/Immunology
    Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Alacizumab
  • HY-P990460
    Anti-LAP Antibody

    		TGF-beta/Smad Inflammation/Immunology
    Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-LAP Antibody
  • HY-P990544
    Anti-vWF Antibody

    		Integrin Inflammation/Immunology
    Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-vWF Antibody
  • HY-P990591
    GSK-1070806

    Aletekitug

    		 Interleukin Related Inflammation/Immunology
    GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    GSK-1070806
  • HY-P990535
    Anti-TSLP Antibody

    		Interleukin Related Inflammation/Immunology
    Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TSLP Antibody
  • HY-P990614
    LK-1

    		Myosin Inflammation/Immunology
    LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    LK-1
  • HY-P990611
    KRN-330

    		Transmembrane Glycoprotein Inflammation/Immunology
    KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    KRN-330
  • HY-P990594
    GSK-679586

    		Interleukin Related Inflammation/Immunology
    GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    GSK-679586
  • HY-P990467
    Anti-MICB Antibody

    		Transmembrane Glycoprotein Inflammation/Immunology
    The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-MICB Antibody
  • HY-P990661
    SAIT-301

    		c-Met/HGFR Inflammation/Immunology
    SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    SAIT-301
  • HY-P990589
    GBR-900

    		Trk Receptor Inflammation/Immunology
    GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    GBR-900

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: